China News Service, Guangzhou, August 11 (Cai Minjie, Lin Zhiwei) Lung cancer is one of the fastest growing malignancies in the Mainland in terms of morbidity and mortality, and about 85% of them are non-small cell lung cancer
Data show that the 5-year survival rate of lung cancer patients diagnosed and treated early can reach more than 90%
With the widespread application of thoracoscopic lobectomy surgery in the Mainland, the overall level of minimally invasive thoracic surgery in the Mainland has led the world.
Although early detection and surgery are curative means to achieve early and mid-stage lung cancer, nearly half of patients diagnosed as early stage and more than three-quarters of patients diagnosed as advanced stage experience recurrence within five years after surgery
"There are generally two risks after early lung cancer surgery, one is local recurrence, and the other is distant metastasis
Wu Yilong said: "Recurrence and metastasis are huge problems faced by patients, family members, and clinicians after NSCLC patients have undergone surgery.
With the continuous advancement of medical standards, the emergence of adjuvant targeted therapy options for patients with EGFR gene mutation-positive lung cancer diagnosed in the early and mid-term has brought new hope for the long-term and high-quality survival of China's early and mid-term lung cancer patients
"In the past, chemotherapy had very low therapeutic effects on brain metastases, but now the third-generation EGFR targeted drugs have very good brain function, so this is a very significant breakthrough
Experts remind that in addition to standard treatment for early and mid-stage lung cancer patients, attention should also be paid to postoperative follow-up
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
